On February 19, 2019, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the 2017 edition of Meds Entry Watch. According to the notice, this publication provides information on new medicines entering Canadian and international markets. The 2017 edition examines the availability, sales, uptake, pricing, and treatment costs of new medicines approved by the US Food and Drug Administration, the European Medicines Agency, and/or Health Canada in 2016 and 2017, as well as trends, going back to 2009. This edition also includes an analysis of biosimilars approved between 2006 and 2017.
Related Publications & Articles
-
CDA releases strategy to improve the appropriate prescribing and use of prescription medications in Canada
On September 18, 2025, Canada’s Drug Agency (CDA) launched its new strategy to improve the appropriate prescribing and use of prescription medications in Canada.Read More -
PMPRB releases Annual Public Drug Plan Expenditure Report (2022/23)
On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) announced the release of CompassRx, an annual report that analyzes factors driving prescription drug expenditures in Canadian pub...Read More -
Ontario pilot program and pCPA new negotiation pathway aim to expedite access to breakthrough cancer treatments
The Ontario government and the pan-Canadian Pharmaceutical Alliance (pCPA) announced separate initiatives in October 2025, both aimed to accelerate patient access to breakthrough cancer treatments app...Read More
